Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Upadacitinib: Mechanism of action, clinical, and translational science

21 Nov 2023

Abstract excerpt

Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases, including rheumatic, dermatologic, and gastrointestinal diseases. Through inhibition of JAK, upadacitinib inhibits phosphorylation of downstream effector proteins,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Inflammatory Bowel Disease
Share to Psoriasis: Treatment and Pathogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37984057
DOI: 10.1111/cts.13688

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Upadacitinib: Mechanism of action, clinical, and translational sciencePMID 37984057Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)Semantic proximity Read ↗

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current InsightsSemantic proximity Read ↗

JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)Semantic proximity Read ↗

Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 StudiesSemantic proximity Read ↗

JAK selectivity: more precision less troublesSemantic proximity Read ↗

Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesSemantic proximity Read ↗

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic InterventionSemantic proximity Read ↗

Efficacy Trajectory and Hematologic Safety of Oral JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Prospective Real-World StudySemantic proximity Read ↗

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibitionSemantic proximity Read ↗

The JAK/STAT conundrum with mutational heterogeneity, immune defects, and the emergence of targeted therapies.Semantic proximity Read ↗

JAK Kinases in Health and Disease: An UpdateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.